- ►ucsf.edu [PDF] JG McHutchison, SC Gordon, ER Schiff, ML … - New England Journal of Medicine, 1998 - content.nejm.org ABSTRACT Background Only 15 to 20 percent of patients with chronic hepatitis C
have a sustained virologic response to interferon therapy. We compared the ef-
ficacy and safety of recombinant interferon alfa-2b alone with those of a ... Cited by 2512 - Related articles - BL Direct - All 11 versions
T Poynard, P Marcellin, SS Lee, C Niederau, … - The Lancet, 1998 - Elsevier 832 patients aged 18 years or more with chronic HCV who had not been treated
with interferon or ribavirin, were enrolled and randomly allocated one of three
regimens: 3 mega units (MU) interferon α2b three times a week plus ... Cited by 1671 - Related articles - All 7 versions
- ►annals.org [PDF] SJ Hadziyannis, H Sette Jr, TR Morgan, V … - Annals of internal medicine, 2004 - Am Coll Physicians Background: Treatment with pegylated interferon (peginter- feron) and ribavirin
for 48 weeks is more effective than conven- tional interferon and ribavirin in
patients with chronic hepatitis C. Objective: To assess the efficacy and ... Cited by 1169 - Related articles - All 8 versions
GL Davis, R Esteban-Mur, V Rustgi, J Hoefs, … - The New England journal of medicine, 1998 - nejm.highwire.org Results At the completion of treatment, serum levels of hepatitis C virus (HCV)
RNA were undetectable in 141 of the 173 patients who were treated with
interferon and ribavirin and in 80 of the 172 patients who were treated ... Cited by 997 - Related articles - BL Direct - All 6 versions
JG McHutchison, M Manns, K Patel, T Poynard … - Gastroenterology, 2002 - spcorp.com.cn JOHN G. MCHUTCHISON,* MICHAEL MANNS,‡ KEYUR PATEL,* THIERRY POYNARD,§ KAREN
L. LINDSAY, CHRISTIAN TREPO,¶ JULES DIENSTAG,# WILLIAM M. LEE,** CARMEN
MAK,‡‡ JEAN–JACQUES GARAUD,‡‡ and JANICE K. ALBRECHT,‡‡ FOR ... Cited by 516 - Related articles - BL Direct - All 9 versions
- ►annals.org TJ Liang, B Rehermann, LB Seeff, JH … - Annals of internal medicine, 2000 - Am Coll Physicians Approximately 4 million persons in the United States and probably more than 100
million persons worldwide are infected with hepatitis C virus. The virus has the
unique ability to cause persistent infection in susceptible hosts after ... Cited by 490 - Related articles - BL Direct - All 5 versions
KL Lindsay, C Trepo, T Heintges, ML … - Hepatology, 2001 - natap.org This international, randomized, active-controlled, paral- lel-group,
double-blind dose-finding study compared pegin- terferon alfa-2b (PegIntron™)
to interferon alfa-2b for the initial treatment of compensated chronic ... Cited by 476 - Related articles - BL Direct - All 6 versions
SA Villano, D Vlahov, KE Nelson, S Cohn, … - Hepatology, 1999 - journals.pasteur.ac.ir The purpose of this investigation was to prospectively characterize acute
hepatitis C virus (HCV) infections and to evaluate the hypothesis that the
outcome is affected by identifiable clinical or viral factors. One hundred ... Cited by 295 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] MS Sulkowski, DL Thomas - Annals of internal medicine, 2003 - Am Coll Physicians Because of shared routes of transmission, hepatitis C virus (HCV) infection is
common in HIV-infected persons, who have been experiencing increasing
HCV-related morbidity and mortality since the advent of effective ... Cited by 279 - Related articles - BL Direct - All 8 versions
